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Summary
The incidence of nephrogenic systemic fibrosis in sub-
jects receiving gadoversetamide for cardiovascular mag-
netic resonance is low (0.026% overall and 1.274% in
those subjects with CKD Stage 5 on hemodialysis).
Background
Since 2006, the US Food and Drug Administration
(FDA) has recommended restricting gadolinium based
contrast agents (GBCAs) for magnetic resonance in
patients with renal impairment due to an association of
GBCA use with nephrogenic systemic fibrosis (NSF).
The multiple FDA warnings have listed different glo-
merular filtration rate (GFR) cut-off values for restrict-
ing GBCA use. Consequently, hospital policies vary in
renal impairment screening criteria and restrictions for
both agent-specific and GFR cut-off values for GBCA
use. Determining the incidence of developing NSF after
exposure to specific GBCAs, and when stratified by
chronic kidney disease (CKD) stage, may clarify which
agents and patients are at highest risk for developing
NSF. Currently, the incidence of developing NSF after
exposure to gadoversetamide (Covidien, Mansfield MA)
is unknown. The objective of this study was to deter-
mine the incidence and patients at highest risk of devel-
oping NSF in a large cohort of patients with suspected
cardiovascular disease receiving gadoversetamide.
Methods
Enrolled adult patients (n=7653) received gadoverseta-
mide for a cardiovascular magnetic resonance (CMR)
imaging study at Duke University Medical Center
between July 1, 2002 and July 31, 2008. All database
creatinine and gadoversetamide doses were verified by
examining the original documentation at the time of the
CMR. Multiple, redundant search strategies were per-
formed in parallel to identify subjects with NSF includ-
ing interrogation of Duke pathology, nephrology, and
other available clinical databases. All search strategies
were cross-matched against one another to verify that
the same patients were identified using each strategy.
For patients with CKD Stages 4 (n=263) and 5 (n=174),
all available medical records were individually examined
with particular attention paid to nephrology, dermatol-
ogy, rheumatology, and pathology encounters. Incidence
of NSF and 95% confidence intervals were determined
overall and stratified by CKD stage.
Results
Two patients developed NSF. See figure 1.
Conclusions
The incidence of developing NSF after exposure to
gadoversetamide is low (overall: 0.026%; CKD Stage 5
on hemodialysis: 1.274%) in the largest cohort to date
examining gadoversetamide. Both NSF patients had
CKD Stage 5 on hemodialysis. Zero patients with Stage
5 CKD not on hemodialysis developed NSF. The wide
95% confidence interval for the latter group is likely due
to the small number of patients (n=44). Further review
is needed to determine if gadoversetamide should be
less restricted in patients with moderate renal impair-
ment in order to offer diagnostic capabilities to those
patients who may suffer detrimental effects due to
delayed or missed diagnoses.
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Figure 1 Incidence of NSF in subjects receiving gadoversetamide for cardiovascular magnetic resonance.
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